Kaleido Biosciences (KLDO) Price & Analysis

196 Followers

KLDO Stock Chart & Stats

$0.20

$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

$0.20

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $0.35

Previous CloseN/A

Volume4.24K

Average Volume (3M)579.00

Market Cap

$4.26K

Enterprise Value-$16.78T

Total Cash (Recent Filing)$38.47M

Total Debt (Recent Filing)$21.69M

Price to Earnings (P/E)―

Beta356.62

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding42,622,560

10 Day Avg. Volume579

30 Day Avg. Volume579

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)9.43

Price to Sales (P/S)90.62

P/FCF Ratio-1.28

Enterprise Value/Market Cap-3.94B

Enterprise Value/Revenue-15.20M

Enterprise Value/Gross Profit-15.20M

Enterprise Value/Ebitda197.15K

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

KLDO FAQ

What was Kaleido Biosciences Inc’s price range in the past 12 months?

Kaleido Biosciences Inc lowest stock price was $0.01 and its highest was $0.35 in the past 12 months.

What is Kaleido Biosciences Inc’s market cap?

Kaleido Biosciences Inc’s market cap is $4.26K.

When is Kaleido Biosciences Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kaleido Biosciences Inc’s earnings last quarter?

Kaleido Biosciences Inc released its earnings results on Nov 01, 2021. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.542 by $0.002.

Is Kaleido Biosciences Inc overvalued?

According to Wall Street analysts Kaleido Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kaleido Biosciences Inc pay dividends?

Kaleido Biosciences Inc does not currently pay dividends.

What is Kaleido Biosciences Inc’s EPS estimate?

Kaleido Biosciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kaleido Biosciences Inc have?

Kaleido Biosciences Inc has 42,622,560 shares outstanding.

What happened to Kaleido Biosciences Inc’s price movement after its last earnings report?

Kaleido Biosciences Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.542. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Kaleido Biosciences Inc?

Currently, no hedge funds are holding shares in KLDO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kaleido Biosciences Inc

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.